Stock CANF CAN-FITE BIOPHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Can-Fite BioPharma Ltd. Nyse

Equities

CANF

US13471N1028

End-of-day quote Nyse
Other stock markets
 18:00:00 2024-02-04 EST 		5-day change 1st Jan Change
2.02 USD -3.35% Intraday chart for Can-Fite BioPharma Ltd. -4.04% -8.18%
05-12 Transcript : Can-Fite BioPharma Ltd. - Special Call
05-09 Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study CI

Evolution of the average Target Price on Can-Fite BioPharma Ltd.

Price target over the last 5 years

History of analyst recommendation changes

adafca7920e65765.zxxGAxLHAP3y9f7ukqJuwOb_lw1gPvHvQ178_QX1Tkg.hmwLT321d4qeo8mJzds9mIm27XwUW5SELzGRmkSmPz6hLgxPeJJPzKKArw~011965984dd3f1b12d87cd79e4c6e721

Analyst Recommendations on Can-Fite BioPharma Ltd.

HC Wainwright Adjusts Can-Fite Biopharma Price Target to $18 From $34, Maintains Buy Rating MT
CAN FITE BIOPHARMA : Aegis Capital Starts Can-Fite Biopharma at Buy with $5 Price Target MT
DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.027
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Can-Fite BioPharma Ltd.

HC Wainwright
Aegis Capital

Ratings for Can-Fite BioPharma Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CANF Stock
  4. CANF Stock
  5. Consensus Can-Fite BioPharma Ltd.